Biotech Drug Report Generated Aug 3, 2026

WTX-124

HOWL·Werewolf Therapeutics, Inc.

BEARISH

Drug Impact Rating3/10

Trial Phase: unknown — not confirmed this session (SecBot's FDA/ClinicalTrials.gov ingestion holds no WTX-124 records; external web s
Time to Market: Unknown — no approval timeline exists in available sources; multi-year (if ever) from its current stage, and the program's future is clouded by the company's strategic review.
Why 3/10: No hard, dated catalyst for WTX-124 is scheduled in the next ~12 months — SecBot's FDA/catalyst/ClinicalTrials.gov ingestion shows no WTX-124 readout, PDUFA, or filing, and the company (HOWL) is in a Piper Sandler-led strategic-alternatives review that could sell or shelve the program, so the drug can only rate 3 (mid-stage asset, no dated binary).

Actionable Insight ▼ BEARISH

Watch the strategic-alternatives process (no defined timeline per the July 31, 2026 Q2 update) — WTX-124's fate is likely a sale/partnership or wind-down rather than a clinical binary. Also watch the cash runway: ~$22.0M at June 30, 2026 against ~$13.8M in quarterly operating expenses, with the company guiding to funding into Q2 2027. Repeated Form 144 filings from backers MPM, RA Capital and UBS Oncology and a 10.3% rise in short positions (July 15 settlement) argue against expecting a near-term squeeze.

Price Chart

Loading chart...

Executive Summary

WTX-124 is a pipeline program at Werewolf Therapeutics (Nasdaq: HOWL), a ~$22M micro-cap that confirmed in its July 31, 2026 Q2 update that it is still developing the drug while reviewing strategic alternatives with Piper Sandler. The company just sold its JZP898 program to Jazz Pharmaceuticals for $21.0M (the entire Q2 revenue), leaving ~$22.0M cash and a runway guided into Q2 2027, with persistent selling by insider/VC holders (MPM, RA Capital, UBS Oncology) and no scheduled WTX-124 clinical catalyst in SecBot's data.

How It Works

Per the company's own description, WTX-124 is part of Werewolf's platform of "conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer": engineered immune-stimulating proteins designed to stay inactive in healthy tissue and switch on in the tumor to prompt the immune system to attack cancer cells.

Trial Status

WTX-124 was named among Werewolf's pipeline programs (with WTX-330, WTX-1011, WTX-2022) in the Q2 2026 earnings materials (8-K filed July 31, 2026), so it is still carried as a program, but no phase, enrollment, readout dates, or results were retrievable this session. Company context: the Q2 2026 8-K reports net income of $3.7M ($0.08 EPS) driven entirely by $21.0M of one-time collaboration revenue from selling the JZP898 program to Jazz Pharmaceuticals, cash down to $22.0M from $46.5M, and an ongoing strategic-alternatives review with Piper Sandler.

The Two-Sided Case

▲ Bull Case4

WTX-124 is still an active pipeline asset — it is named among Werewolf's drug programs (WTX-124, WTX-330, WTX-1011, WTX-2022) in the Q2 2026 8-K, meaning it has not been discontinued or sold off like JZP898.

The platform concept is differentiated and the company is debt-free with ~$22.0M cash and guidance to fund operations into Q2 2027, giving some time for a strategic outcome.

Sell-side remains constructive on the name: July 2026 consensus shows 4 buy + 4 strong buy vs 2 hold (0 sell), and Wedbush's rated calls on HOWL score 100% accuracy (top tier) in SecBot's benchmark.

The strategic-alternatives process (and the JZP898 sale precedent at $21.0M) means WTX-124 could be monetized via out-licensing or a company sale rather than going extinct.

▼ Bear Case5

No hard, dated catalyst for WTX-124 exists in the next ~12 months in any available source — no PDUFA, no scheduled readout, no trial records in SecBot's FDA/ClinicalTrials.gov data.

Cash crunch: $22.0M cash at June 30, 2026 (down from $46.5M at Q1 end) against ~$13.8M quarterly operating expenses; Q2's $0.08 EPS 'beat' was 100% a one-time asset sale, masking ongoing losses, and management says the strategic review has no defined timeline or guarantee.

Coordinated selling by pre-IPO backers: multiple Form 144s from MPM-affiliated funds, UBS Oncology Impact Fund, and 10% owner RA Capital, plus director Luke Evnin 10b5-1 sales — with no insider buys recorded.

Sell-side price targets have been cut repeatedly (HC Wainwright $10 to $4, BofA $8 to $7, JMP $4 to $3 across 2025), and the stock trades at ~$0.36, near its 52-week low of $0.27.

Elevated short-volume flow (57.7% of off-exchange volume on July 24, 2026; 59.2% on June 8) plus a 10.3% increase in FINRA short positions (934,340 shares at the July 15 settlement) point to persistent downward pressure, while % of shares outstanding short is only ~1.92% with ~1.0 days-to-cover — no squeeze setup.

Upcoming Catalysts

Outcome of the strategic-alternatives review with Piper Sandler (no defined timeline; potential sale, merger, or asset divestiture of WTX-124/WTX-1011/WTX-2022)
Any WTX-124 clinical data disclosure in future earnings or conference updates (undated in available sources)
Cash-runway updates in Q3/Q4 2026 earnings reports
Further insider/Form 144 selling or any equity financing/dilution

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Werewolf Therapeutics, Inc. 8-K HOWL ·Originating report

Sources · 6

Hover a chip for the title

1 globenewswire.com2 globenewswire.com3 sec.gov4 sec.gov5 sec.gov6 sec.gov